









市場行情
/
股票
/
nasdaq-abcl
/

Abcellera Biologics Inc

ABCL

3.720USD

+0.030+0.81%

收盤 12/24, 13:00（美東）報價延遲15分鐘

1.11B總市值

虧損本益比TTM



Abcellera Biologics Inc

3.720

+0.030+0.81%

概覽公司財務分析

概覽

公司

財務

分析

關於 Abcellera Biologics Inc 公司

AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

Abcellera Biologics Inc簡介



公司代碼ABCL

公司名稱Abcellera Biologics Inc

上市日期Dec 11, 2020

CEOHansen (Carl L.G)

員工數量596

證券類型Ordinary Share

年結日Dec 11

公司地址150 W 4Th Avenue

城市VANCOUVER

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Canada

郵編V5Y 1G6

電話16045599005

網址https://www.abcellera.com/

公司代碼ABCL

上市日期Dec 11, 2020

CEOHansen (Carl L.G)

Abcellera Biologics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Veronique Lecault, Ph.D.

Co-Founder, Chief Operating Officer, Director

9.61M

Mr. Andrew Booth

Chief Financial Officer

283.96K

Mr. Stephen Quake

Independent Director

Mr. Tryn T. Stimart, J.D.

Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer

Mr. John S. Montalbano

Independent Director

Dr. Carl L.G. Hansen, Ph.D.

Chairman of the Board, President, Chief Executive Officer, Co-Founder

Dr. Sarah B. Noonberg, M.D., Ph.D.

Chief Medical Officer

Dr. Michael R. Hayden

Lead Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Veronique Lecault, Ph.D.

Co-Founder, Chief Operating Officer, Director

9.61M

Mr. Andrew Booth

Chief Financial Officer

283.96K

Mr. Stephen Quake

Independent Director

Mr. Tryn T. Stimart, J.D.

Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer

Mr. John S. Montalbano

Independent Director

Dr. Carl L.G. Hansen, Ph.D.

Chairman of the Board, President, Chief Executive Officer, Co-Founder

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2024Q2

FY2023Q2

業務USD

名稱

營收

佔比

Licensing revenue

10.45M

61.14%

Research fees

6.64M

38.86%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

Licensing revenue

10.45M

61.14%

Research fees

6.64M

38.86%

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

Thermopylae Holdings Ltd

18.68%

Baker Bros. Advisors LP

9.20%

Capital World Investors

4.46%

Baillie Gifford & Co.

3.48%

Two Sigma Investments, LP

3.34%

其他

60.84%

持股股東

佔比

Thermopylae Holdings Ltd

18.68%

Baker Bros. Advisors LP

9.20%

Capital World Investors

4.46%

Baillie Gifford & Co.

3.48%

Two Sigma Investments, LP

3.34%

其他

60.84%

股東類型

持股股東

佔比

Corporation

18.76%

Hedge Fund

16.32%

Investment Advisor

13.67%

Individual Investor

4.16%

Investment Advisor/Hedge Fund

4.14%

Research Firm

2.06%

Bank and Trust

0.87%

Pension Fund

0.29%

Sovereign Wealth Fund

0.21%

其他

39.51%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

315

112.27M

50.73%

-101.09K

2025Q3

340

112.51M

51.75%

-3.28M

2025Q2

368

115.12M

53.94%

-18.45M

2025Q1

420

133.63M

52.62%

-23.37M

2024Q4

441

121.95M

50.14%

+4.83M

2024Q3

440

121.95M

51.59%

-4.54M

2024Q2

439

127.07M

51.27%

-6.55M

2024Q1

432

134.44M

53.43%

-22.43M

2023Q4

425

138.44M

60.93%

-1.40M

2023Q3

426

134.18M

60.12%

-4.59M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Thermopylae Holdings Ltd

56.14M

18.79%

Apr 01, 2025

Baker Bros. Advisors LP

27.53M

9.21%

Jun 30, 2025

Capital World Investors

13.36M

4.47%

Jun 30, 2025

Baillie Gifford & Co.

10.36M

3.47%

-835.83K

-7.47%

Jun 30, 2025

Two Sigma Investments, LP

8.18M

2.74%

+2.41M

+41.75%

Jun 30, 2025

Lecault (Veronique)

9.61M

3.22%

Apr 01, 2025

ArrowMark Colorado Holdings, LLC

4.11M

1.37%

Jun 30, 2025

Renaissance Technologies LLC

3.31M

1.11%

+413.40K

+14.28%

Jun 30, 2025

Tang Capital Management, LLC

2.60M

0.87%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Genomics Immunology and Healthcare ETF

2.64%

Virtus LifeSci Biotech Clinical Trials ETF

1.19%

ProShares Ultra Nasdaq Biotechnology

0.16%

Invesco Nasdaq Biotechnology ETF

0.16%

SPDR S&P International Small Cap ETF

0.12%

iShares Biotechnology ETF

0.11%

Invesco RAFI Developed Mkts ex-US SM ETF

0.05%

Avantis US Small Cap Equity ETF

0.01%

SPDR Portfolio Developed World ex-US ETF

0.01%

Fidelity Nasdaq Composite Index ETF

0.01%

iShares Genomics Immunology and Healthcare ETF

佔比2.64%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.19%

ProShares Ultra Nasdaq Biotechnology

佔比0.16%

Invesco Nasdaq Biotechnology ETF

佔比0.16%

SPDR S&P International Small Cap ETF

佔比0.12%

iShares Biotechnology ETF

佔比0.11%

Invesco RAFI Developed Mkts ex-US SM ETF

佔比0.05%

Avantis US Small Cap Equity ETF

佔比0.01%

SPDR Portfolio Developed World ex-US ETF

佔比0.01%

Fidelity Nasdaq Composite Index ETF

佔比0.01%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Abcellera Biologics Inc的前五大股東是誰？



Abcellera Biologics Inc的前五大股東如下：
Thermopylae Holdings Ltd
持有股份：56.14M
佔總股份比例：18.79%。
Baker Bros. Advisors LP
持有股份：27.53M
佔總股份比例：9.21%。
Capital World Investors
持有股份：13.36M
佔總股份比例：4.47%。
Baillie Gifford & Co.
持有股份：10.36M
佔總股份比例：3.47%。
Two Sigma Investments, LP
持有股份：8.18M
佔總股份比例：2.74%。